Evidence map›Paper›PMID 41451842›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Mesial temporal tau pathology impacts basal forebrain degeneration in early Alzheimer's disease.

Ying Xia, Matthew W Dean, Pierrick Bourgeat, Natasha Krishnadas, Paul Maruff, Colin L Masters, Victor L Villemagne, Jurgen Fripp, Christopher C Rowe, Vincent Doré and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. A lifespan staging model of basal forebrain cholinergic vulnerability.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  2. Mesial temporal tau pathology impacts basal forebrain degeneration in early Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ying XiaThe Australian e-Health Research Centre, CSIRO Health and Biosecurity, Herston, Queensland, Australia.ORCID 0000-0003-3107-7759
Matthew W DeanSchool of Biomedical Sciences, The University of Queensland, Brisbane, St. Lucia, Queensland, Australia.
Pierrick BourgeatThe Australian e-Health Research Centre, CSIRO Health and Biosecurity, Herston, Queensland, Australia.
Natasha KrishnadasDepartment of Molecular Imaging & Therapy, Austin Health, Heidelberg, Victoria, Australia.
Paul MaruffThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.
Colin L MastersThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.
Victor L VillemagneDepartment of Molecular Imaging & Therapy, Austin Health, Heidelberg, Victoria, Australia.
Jurgen FrippThe Australian e-Health Research Centre, CSIRO Health and Biosecurity, Herston, Queensland, Australia.
Christopher C RoweDepartment of Molecular Imaging & Therapy, Austin Health, Heidelberg, Victoria, Australia.
Vincent DoréDepartment of Molecular Imaging & Therapy, Austin Health, Heidelberg, Victoria, Australia.
Elizabeth J CoulsonSchool of Biomedical Sciences, The University of Queensland, Brisbane, St. Lucia, Queensland, Australia.

Funding

National Health and Medical Research Council GNT2019129
6 · The paper itself

Abstract

introductionThe cholinergic basal forebrain system, particularly the nucleus basalis of Meynert (Ch4), is selectively vulnerable to amyloid beta (Aβ) and tau in Alzheimer's disease (AD). Their interplay may be a critical driver of AD progression, but remains poorly understood.

methodsData from 779 older individuals in the Australian Imaging, Biomarker, and Lifestyle study were analyzed, all of whom underwent

resultsThe co-occurrence of Aβ and mesial-temporal (MTL) tau pathologies was associated with reduced Ch4 volumes in cognitively unimpaired individuals. MTL tau burden was associated with Ch4 volumes exclusively in cognitively unimpaired individuals with established Aβ pathology, which was not observed for the hippocampus. This association persists in individuals with mild cognitive impairment, but was not apparent in AD dementia. DISCUSSION: Findings underscore early Ch4 degeneration associated with Aβ and tau pathologies, supporting potential cognitive benefits of cholinergic therapies in early disease stages. HIGHLIGHTS: Early-stage tau pathology in the mesial-temporal (MTL) region was assessed using

Indexed as

Alzheimer DiseaseBasal ForebrainBasal Nucleus of Meynerttau ProteinsTemporal LobeAgedAged, 80 and overAmyloid beta-PeptidesAustraliaCognitive DysfunctionFemaleHumansMagnetic Resonance ImagingMalePositron-Emission TomographyAmyloid beta-Peptidestau Proteins[18F]MK‐6240Alzheimer's diseaseamyloid imagingbasal forebrain volumehippocampal volumemagnetic resonance imagingpositron emission tomographytau pathology

Identifiers

PMID41451842
PMCPMC12741919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.